News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC
Photo from Drew Moghanaki/X
Sep 2, 2024, 08:32

Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC

Drew Moghanaki shared a post on X about a paper by Gregory Videtic et al. published in PubMed.

“Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer”

Authors: Gregory Videtic, Chandana Reddy, Neil Woody, Kevin Stephans

Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC

“Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC. How about others?”

Source: Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).

cancer Chandana Reddy Drew Moghanaki Gregory Videtic Kevin Stephans Neil Woody non small cell lung cancer NSCLC OncoDaily Oncology Pubmed radiation oncology UCLA
Special Coverage
Opinion
Nov 13, 2024, 10:32
The 6th Biennial Miami Epigenetics and Cancer Symposium to be held in Sylvester Comprehensive Cancer Center
Blog
Nov 13, 2024, 10:16
Highlights from IU Simon Comprehensive Cancer Center’s End Lung Cancer Now Gathering - Hoosier Cancer Research Network
Blog
Nov 13, 2024, 10:06
A first-in-class Antibody Drug Conjugate that works by directly stimulating the immune system
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology
Insight
Nov 13, 2024, 09:27
Nikki Rossetti et al. on Early-Stage Lung Cancer in the Era of Lung Cancer Screening
Blog
Nov 13, 2024, 09:14
Yüksel Ürün: Key takeaways on high-risk and locally advanced prostate cancer from António Rui Azevedo Freitas
Blog
Nov 13, 2024, 09:11
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy
Blog
Nov 13, 2024, 09:09
Yüksel Ürün: Not all that shines is Prostate cancer – a striking reminder from Daniela Oprea-Lager
Blog
Nov 13, 2024, 09:01
Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer
Blog
Nov 13, 2024, 08:59
Miriam Mutebi: What To Expect During A Mammogram
Insight
Nov 13, 2024, 08:56
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors